Eledon Pharmaceuticals (ELDN) Consolidated Net Income (2013 - 2026)
Eledon Pharmaceuticals (ELDN) posted Consolidated Net Income of -$21.3 million for Q1 2026, down 7.13% on a QoQ basis from -$19.9 million in Q3 2025, and down 12.28% year-over-year from -$24.3 million in Q1 2025.
Eledon Pharmaceuticals (ELDN) Consolidated Net Income (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Consolidated Net Income history runs 14 years deep, the most recent figure standing at -$21.3 million for Q1 2026.
- Quarterly Consolidated Net Income fell 12.28% year-over-year to -$21.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.8 million (up 16.44% YoY) and the FY2025 annual result came in at -$45.6 million, down 26.07% from the prior year.
- Consolidated Net Income was -$21.3 million for Q1 2026 at Eledon Pharmaceuticals, down from -$19.9 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$9.2 million in Q2 2022 and bottomed at -$58.4 million in Q4 2022.
- A 5-year average of -$18.1 million and a median of -$13.4 million in 2023 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income sank 563.0% — and 2023, when it surged 82.12%.
- Eledon Pharmaceuticals' Consolidated Net Income stood at -$58.4 million in 2022, then jumped by 82.12% to -$10.4 million in 2023, then sank by 137.64% to -$24.8 million in 2024, then increased by 19.91% to -$19.9 million in 2025, then fell by 7.13% to -$21.3 million in 2026.
- Business Quant data shows ELDN's Consolidated Net Income at -$21.3 million in Q1 2026, -$19.9 million in Q3 2025, and -$25.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Eledon Pharmaceuticals | 5.43 Mn | -105.66 Mn | - | -21.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.28 Mn |
| Sep 30, 2025 | -19.87 Mn |
| Jun 30, 2025 | -25.63 Mn |
| Mar 31, 2025 | -18.95 Mn |
| Dec 31, 2024 | -24.80 Mn |
| Sep 30, 2024 | -20.98 Mn |
| Jun 30, 2024 | -15.18 Mn |
| Mar 31, 2024 | -11.16 Mn |
| Dec 31, 2023 | -10.44 Mn |
| Sep 30, 2023 | -11.69 Mn |
| Jun 30, 2023 | -10.94 Mn |
| Mar 31, 2023 | -11.19 Mn |
| Dec 31, 2022 | -58.38 Mn |
| Sep 30, 2022 | -10.47 Mn |
| Jun 30, 2022 | -9.25 Mn |
| Mar 31, 2022 | -9.86 Mn |
| Dec 31, 2021 | -8.81 Mn |
| Sep 30, 2021 | -9.82 Mn |
| Jun 30, 2021 | -7.38 Mn |
| Mar 31, 2021 | -8.50 Mn |